Symptom experience after discontinuing use of estrogen plus progestin

JAMA

Volumn 294, Issue 2, 2005, Pages 183-193

  Ockene, Judith K ^a   Barad, David H ^b   Cochrane, Barbara B ^c   Larson, Joseph C ^c   Gass, Margery ^d   Wassertheil Smoller, Sylvia ^b   Manson, JoAnn E ^e   Barnabei, Vanessa M ^f   Lane, Dorothy S ^g   Brzyski, Robert G ^h   Rosal, Milagros C ^a   Wylie Rosett, Judy ^b   Hays, Jennifer ⁱ  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

^g STONY BROOK UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE;

ADRENERGIC SYSTEM; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DEPRESSION; DISEASE SEVERITY; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; JOINT STIFFNESS; LOGISTIC REGRESSION ANALYSIS; PAIN; PRIORITY JOURNAL; RIGIDITY; VASOMOTOR DISORDER; AGED; ANXIETY; CONTROLLED CLINICAL TRIAL; CROSS-SECTIONAL STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; MENOPAUSE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; WITHDRAWAL SYNDROME;

AGED; ANXIETY; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; LOGISTIC MODELS; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; PAIN; PROGESTINS; RANDOMIZED CONTROLLED TRIALS; SUBSTANCE WITHDRAWAL SYNDROME; VASOMOTOR SYSTEM;

EID: 22144475839     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.294.2.183     Document Type: Article

References (36)

1. Blumel J, Castelo-Branco C, Chedraudi P, et al. Patients' and clinicians' attitudes after the Women's Health Initiative study. Menopause. 2004;11:57-61.
2. Hersh A, Stefanick M, Stafford R. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291:47-53.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled clinical trial. JAMA. 2002;288:321-333.
4. Greendale G, Reboussin B, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol. 1998;92:982-988.
5. Barnabei V, Grady D, Stovall D, et al. Menopausal symptoms in older women and the effects of treatment with hormone therapy. Obstet Gynecol. 2002;100:1209-1218.
6. Rothert M, Padonu G, Holmes-Rovner M, et al. Menopausal women as decision makers in health care. Exp Gerontol. 1994;29:463-468.
7. Zethraeus N, Johannesson M, Henriksson P, Strand R. The impact of hormone replacement therapy on quality of life and willingness to pay. Br J Obstet Gynaecol. 1997;104:1191-1195.
8. North American Menopause Society. Estrogen and progestin use in peri- and postmenopausal women: September 2003 position statement. Available at: http://www.menopause.org/positionstatement.pdf. Accessed September 17, 2003.
9. American College of Obstetricians and Gynecologists. Questions and answers on hormone therapy in response to the Women's Health Initiative Study results on estrogen and progestin hormone therapy. Available at: http://www.acog.org /from_home/publications/press_releases/nr08-30-02.cfm. Accessed March 29, 2004.
10. Food and Drug Administration. FDA updates hormone therapy information for post menopausal women. Available at: http://www.fda.gov/bbs/topics/NEWS/2004/ NEW01022.html. Accessed March 20, 2004.
11. Treatment of menopause-associated vasomotor symptoms: position statement of the North American Menopause Society. Menopause. 2004;11:11-33.
12. Newton K, Buist D, Keenan N, Anderson L, LaCroix A. Use of alternative therapies for menopause symptoms: results of a population-based survey. Obstet Gynecol. 2002;100:18-25.
13. Hays J, Hunt J, Hubbell F, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13:S18-S77.
14. Matthews K, Shumaker S, Bowen D, et al. Women's Health Initiative: why now? what is it? what's new? Am Psychol. 1997;52:101-116.
15. Stefanick M, Cochrane B, Hsia J, et al. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13(suppl 9):S78-S86.
16. Barnabei V, Cochrane B, Aragaki A, et al. The effects of estrogen plus progestin on menopausal symptoms and treatment effects among participants of the Women's Health Initiative. Obstet Gynecol. In press.
17. Hays J, Ockene J, Brunner R, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348:1839-1854.
18. Freedman L, Anderson G, Kipnis V, et al. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Control Clin Trials. 1996;17:509-525.
19. Collins D. Pretesting survey instruments: an overview of cognitive methods. Qual Life Res. 2003;12:229-238.
20. Drennan J. Cognitive interviewing: verbal data in the design and pretesting of questionnaires. J Adv Nurs. 2003;42:57-63.
21. Barrett-Connor E, Hendrix S, Ettinger B, et al. Best Clinical Practices. Washington, DC: National Institutes of Health; 2002.
22. National Institute on Aging. Menopause: One Woman's Story, Every Woman's Story: A Resource for Making Healthy Choices. Washington, DC: National Institutes of Health; 2001.
23. North American Menopause Society. Menopause Guidebook. Cleveland, Ohio: North American Menopause Society; 2003.
24. Spitzer R, Kroenke K, Williams J. Validation and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study. JAMA. 1999;282:1737-1744.
25. Hosmer D, Lemeshow S. Applied Logistic Regression, 2000. New York, NY: John Wiley & Sons; 2000.
26. Grady D, Ettinger B, Tosteson A, Pressman A, Macer J. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol. 2003;102:1233-1239.
27. Hammar M, Ekblad S, Lönnberg B, et al. Postmenopausal women without previous or current vasomotor symptoms do not flush after abruptly abandoning estrogen replacement therapy. Maturitas. 1999;31:117-122.
28. Gordon S, Walsh B, Ciaccia A, et al. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol. 2004;103:267-273.
29. Nevitt M, Felson D, Williams E, Grady D; Heart and Estrogen/Progestin Replacement Study Research Group. The effect of estrogen plus progrestin on knee symptoms and related disability in postmenopausal women. Arthritis Rheum. 2001;44:811-818.
30. Hannan M, Felson D, Anderson J, Naimark A, Kannel W. Estrogen use and radiographic osteoarthritis of the knee in women: the Framingham Osteoarthritis Study. Arthritis Rheum. 1990;33:525-532.
31. Reginster J-Y, Kvasz A, Bruyere O, Henrotin Y. Is there any rationale for prescribing hormone replacement therapy (HRT) to prevent or to treat osteoarthritis? Osteoarthritis Cartilage. 2003;11:87-91.
32. Gordon F, Soliman M. The effects of estradiol and progesterone on pain sensitivity and brain opioid receptors in ovariectomized rats. Horm Behav. 1996;30:244-250.
33. American College of Obstetricians and Gynecologists. Osteoarthritis. Obstet Gynecol. 2004;104:62S-65S.
34. Avis N, Stellato R, Crawford S, et al. Is there a menopausal syndrome? menopausal status and symptoms across racial/ethnic groups. Soc Sci Med. 2001;52:345-356.
35. Conboy L, Domar A, O'Connell E. Women at midlife: symptoms, attitudes, and choices, an Internet-based survey. Maturitas. 2001;38:129-136.
36. Will C, Fowles W. Woman to woman: complementary therapy use in menopause. J Holist Nurs. 2003;21:368-382.